/ima
Mental health care for all, no prescription necessary
Our digital therapeutics are safe and effective non-drug alternatives for mental health.*
Most people in need of mental health care don’t receive it
For those who are able to get care, 82% are given medication – but medication isn’t always the best option.1
Our digital therapeutics deliver effective help with no serious side effects
Daylight and Sleepio are easily accessible, safe, and highly effective.6,7
Looking for more information?
Please explore the US or UK version of our site for more information on Big Health and our therapeutics.
Contact us to learn more about our digital therapeutics
Have questions, feedback, or trouble signing up for Sleepio or Daylight?
Email us at hello@bighealth.com instead of submitting this form. While we strive to answer all inquiries within 24 hours, this email is not monitored 24/7.
*Disclaimer: In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.
1. Terlizzi, E. P., & Zablotsky, B. (2020). Mental Health Treatment Among Adults: United States, 2019. NCHS Data Brief, (380), 1-8.
2. Lembke, A., Papac, J., & Humphreys, K. (2018). Our other prescription drug problem. The New England journal of medicine, 378(8), 693-695.
3. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 40(2), zsw044.
4. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. The Journal of clinical psychiatry, 63(suppl 14), 9-16.
5. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 0-0.
6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
7. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
